APCerna

APCerna is a biotechnology company based in the United States, specializing in the development of novel therapeutics for the treatment of cancer and other serious diseases. The company was founded in 2013 and is headquartered in San Diego, California. APCerna's primary focus is on the discovery and development of antibody-drug conjugates (ADCs), which are a type of targeted therapy that combines the specificity of monoclonal antibodies with the potency of cytotoxic drugs.

The company's pipeline includes several promising ADC candidates, each targeting specific cancer types or pathways. These candidates are designed to deliver potent cytotoxic payloads directly to cancer cells, minimizing off-target effects and maximizing therapeutic efficacy. APCerna's approach leverages its proprietary ADC technology platform, which enables the creation of highly potent and selective ADC therapeutics.

APCerna collaborates with various academic institutions, research organizations, and pharmaceutical companies to advance its ADC candidates through preclinical and clinical development. The company's mission is to improve patient outcomes by delivering innovative and effective cancer treatments. As of the latest available information, APCerna continues to advance its pipeline and explore new therapeutic opportunities in oncology and beyond.